Is Osimertinib Better Alone or With Chemotherapy in NSCLC?

A new study reveals that baseline EGFR mutations may be key to making the decision in the frontline setting.

Related Keywords

Boston ,Massachusetts ,United States ,Illinois ,University Of Chicago ,Chicago ,Dana Farber Cancer Institute ,San Diego ,California ,American ,Marina Garassino ,Clinical Research Annual Meeting ,American Association ,Astrazeneca ,Drug Administration ,American Association For Clinical Research Annual ,Pasi Janne ,Lung Cancer ,Ung Carcinoma ,Ancer Of The Lung ,Non Small Cell Lung Cancer ,Nsclc ,Genomics Genomic Medicine ,Small Cell Lung Cancer ,At Cell Lung Cancer ,Clc ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Chemotherapy ,Toxicology ,Toxicity ,Poisoning ,Toxins ,Malignant Head And Neck Neoplasm ,Head And Neck Cancer ,Ead And Neck Cancer Hnc ,Metastasis ,